Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

September 17, 2009 Approval Letter - Havrix

September 17, 2009

Our STN:  BL 103475/5291

GlaxoSmithKline Biologicals
Attention:  Wendy A. Valinski
2301 Renaissance Boulevard
P.O. Box 61540                                                                     
King of Prussia, PA 19406-2772

Dear Ms. Valinski:

We have approved your request to supplement your biologics license application for Hepatitis A Vaccine, Inactivated, Havrix®, to include changes to the package insert regarding the possibility of cracked vials or syringes. 

Please submit all final printed labeling and implementation information on FDA Form 356h. Please provide a PDF-format electronic copy.

We will include information contained in the above-referenced supplement in your biologics license application file.   

Sincerely yours,


Wellington Sun, M.D.
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
Attachment:  Approved Final Draft Labeling

Resources for You

Page Last Updated: 09/23/2009
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English